Cowen & Co. analyst Yaron Werber maintained a Buy rating on BeiGene Ltd (BGNE) today and set a price target of $170. The company’s shares closed last Monday at $146.04.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 11.4% and a 65.6% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Prevail Therapeutics Inc.
BeiGene Ltd has an analyst consensus of Strong Buy, with a price target consensus of $182.60, which is a 25.8% upside from current levels. In a report issued on August 9, Maxim Group also maintained a Buy rating on the stock with a $170 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $182.31 and a one-year low of $105.19. Currently, BeiGene Ltd has an average volume of 253.3K.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290).
